A higher burden of metabolic issues were found in people living with HIV in a study published in HIV Research & Clinical Practice. 1 Despite this increased burden, however, individuals living with HIV ...

Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...

A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability ...

The Trump administration has eliminated $2 million in HIV research facility funding for Meharry Medical College after the ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

New study findings could change treatments for HIV in young children. HIV remission may be possible for very young children ...

Knowing how to leverage these technologies means we can help set the new standard and inform the next evolution of HIV care.

Indian companies to sell generic HIV prevention drug for $40/year by 2027, aiming to end AIDS crisis globally.

The plan to target pregnant and breastfeeding mothers will be administered through PEPFAR. Critics said it appeared to ...

Patients with HIV experienced more delayed, interrupted, and less robust sleep and rest-activity rhythms compared with those ...

Gilead offers a meaningful upside opportunity should it execute on increasing revenue growth to the low-to-middle single ...

A man living with advanced HIV carried COVID-19 for more than 750 days. During the chronic infection, the virus mutated ...